New hope for lung cancer patients whose targeted therapy has failed

NCT ID NCT06868836

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated May 23, 2026

Summary

This study tests a new drug called JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow, in combination with other treatments. It is for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). About 78 participants will receive either JS207 plus chemotherapy or JS207 plus another experimental drug (JS212). The goal is to see if these combinations can shrink tumors and how safe they are.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Guangdong Provicial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

NON SQUAMOUS NON-SMALL CELL LUNG CANCER